PAVmed ( (PAVM) ) just unveiled an update.
PAVmed Inc. has announced strategic changes to regain compliance with Nasdaq’s listing requirements, including the deconsolidation of Lucid Diagnostics from its financial statements. This move improves PAVmed’s balance sheet by removing Lucid’s operating losses and reporting Lucid’s stock as an asset. Additionally, the company has reshuffled its board, appointing biotech expert Dr. Sundeep Agrawal in place of outgoing directors, enhancing its leadership with his experience in strategic transactions and investments. PAVmed is actively pursuing alternatives to maintain its Nasdaq listing, with a hearing anticipated in October to address the recent non-compliance notice regarding its market value.
For a thorough assessment of PAVM stock, go to TipRanks’ Stock Analysis page.
